Literature DB >> 11757637

Lung cancer screening by low-dose spiral computed tomography.

R J van Klaveren1, J H Pedersen, H J de Koning, M Oudkerk, H C Hoogsteden.   

Abstract

The poor prognosis of lung cancer has barely changed in the last decades, but the prognosis is better when the disease is detected earlier. Lung cancer screening by chest radiography did not lead to a decrease in lung cancer mortality, presumably because the chest radiograph is a poor screening tool with low sensitivity. With the advent of the low-dose spiral computed tomography (CT) scan it has become feasible to detect early invasive stage I lung cancer in 8-90% of cases. This technique could possibly decrease lung cancer mortality, but the extent of this effect is as yet unknown, and whether lung cancer screening will be cost-effective is yet to be determined. These questions can only be resolved in a randomized controlled trial with lung cancer mortality as an unbiased end-point. In this review, the initiatives to evaluate low dose spiral CT screening for lung cancer in Japan, USA and Europe are presented. In the USA and Japan, evaluation is in one-armed studies, whereas in many European countries randomized trials are now being planned and several one-armed studies have been initiated. A formal collaboration among these countries has now been set up. It is strongly recommended that lung cancer screening be evaluated in randomized trials in order to allow evidence-based health policy decisions to be made on this subject.

Entities:  

Mesh:

Year:  2001        PMID: 11757637     DOI: 10.1183/09031936.01.00076701

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

Review 1.  Smoking cessation and lung cancer screening.

Authors:  Jesper Holst Pedersen; Philip Tønnesen; Haseem Ashraf
Journal:  Ann Transl Med       Date:  2016-04

2.  Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials.

Authors:  Muralikrishna Gopal; Shaad E Abdullah; James J Grady; James S Goodwin
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

3.  Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round.

Authors:  N Becker; E Motsch; M-L Gross; A Eigentopf; C P Heussel; H Dienemann; P A Schnabel; L Pilz; M Eichinger; D-E Optazaite; M Puderbach; J Tremper; S Delorme
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-21       Impact factor: 4.553

Review 4.  Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature.

Authors:  Corri Black; Robyn de Verteuil; Shonagh Walker; Jon Ayres; Angela Boland; Adrian Bagust; Norman Waugh
Journal:  Thorax       Date:  2007-02       Impact factor: 9.139

Review 5.  Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review).

Authors:  Mudit Vaid; Joanna Floros
Journal:  Oncol Rep       Date:  2009-01       Impact factor: 3.906

6.  Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study.

Authors:  Olaide Y Raji; Stephen W Duffy; Olorunshola F Agbaje; Stuart G Baker; David C Christiani; Adrian Cassidy; John K Field
Journal:  Ann Intern Med       Date:  2012-08-21       Impact factor: 25.391

7.  Detection of pulmonary nodules by multislice computed tomography: improved detection rate with reduced slice thickness.

Authors:  Frank Fischbach; Friedrich Knollmann; Volker Griesshaber; Torsten Freund; Ethem Akkol; Roland Felix
Journal:  Eur Radiol       Date:  2003-05-13       Impact factor: 5.315

8.  Could CT screening for lung cancer ever be cost effective in the United Kingdom?

Authors:  David K Whynes
Journal:  Cost Eff Resour Alloc       Date:  2008-02-26

Review 9.  DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.

Authors:  Paul P Anglim; Todd A Alonzo; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

10.  Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

Authors:  E L Crawford; A Levin; F Safi; M Lu; A Baugh; X Zhang; J Yeo; S A Khuder; A M Boulos; P Nana-Sinkam; P P Massion; D A Arenberg; D Midthun; P J Mazzone; S D Nathan; R Wainz; G Silvestri; J Tita; J C Willey
Journal:  BMC Pulm Med       Date:  2016-01-22       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.